Pulmonary Drug Delivery Technologies

Published by: Global Industry Analysts

Published: May. 1, 2008 - 319 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Metered Dose Inhalers (MDIs)

Dry Powder Inhalers (DPIs)

Nebulizers

II. EXECUTIVE SUMMARY

1. Market Dynamics

Market Overview

Pulmonary Devices: Gaining Pace

Market Highlights

Primary Position of the U.S

Pulmonary Drug Delivery: An Attractive Non-Invasive Option

Chief Pulmonary Delivery Technologies

Most Effective Route for Respiratory Syndromes

Leading Inhalation Prescription Drugs Across All Segments

The Attractiveness of Inhalers

Choice of Drug Delivery System

Inhalation Therapy: A Retrospection

Pulmonary Drug Delivery - Market Snapshots

2. Trends and Issues

Market Snippets

Focus of New Age Pulmonary Devices

Dry Powder Inhalation: A Promising Technology

Research Activities in Inhaled Drug Delivery

Lung Versus Oropharyngeal Deposition: A Major Challenge

Competitive Environment

A Backdrop

Market Leaders

Table 1: World Market for Inhaled Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Major Brands- Flovent, Serevent, Pulmicort, Atrovent, Ventolin, and Others (includes corresponding Graph/Chart)

Industry Efforts

Inefficient Use of Pulmonary Drug Delivery Systems

MDIs

Spacers

Dry Powder Inhalers

Issues Facing Various Inhalation Devices

Jet Nebulizers

MDIs

DPIs

3. Growth Drivers

Growth Drivers in Pulmonary Drug Delivery

Use of Nano Technology in Drug Delivery Products

Other Growth Areas

Table 2: World Market for Pulmonary Drug Delivery Technologies (2000 & 2005): Percentage Share Breakdown of Sales by Drug Category- Bronchodilators, Anti-Inflammatories, Protein/Peptide Therapeutics, Combination, and Other Small Molecule (includes corresponding Graph/Chart)

Innovative Pulmonary Devices Shape Progress

Pulmonary Insulin

Alternative Drug Delivery Systems: A Review

Market Size

Inhaled Small Molecule Therapeutics

4. Product Overview

Definition of Pulmonary Drug Delivery System

Pulmonary Drug Delivery Technologies: An Introduction

An Overview of Key Features of Popular Inhalation Devices

Product Segments

A. Nebulizers

Nebulizers: Key Devices for Bronchodilator Delivery

Working Principle of a Nebulizer

Use of UDMs in Nebulizers

Types of Nebulizers

Ultrasonic Nebulizers

Device Components

Gray Areas

Benefits

Limitations

Pneumatic Nebulizers

Breath-Actuated Nebulizers

Continuous Nebulization

Nebulizers for Specific Applications

Active Venturi Nebulizers

New Designs for Improved Nebulizer Performance

Limitations of Nebulizers

Nebulizers and MDIs

B. Metered Dose Inhalers (MDIs)

Working Principle of an MDI

MDI Timeline

CFC-Propellant based MDIs

Ban on CFCs

Use of Spacers in MDIs

Benefits of Spacers

Types of Spacers

Issue of Electrostatic Charge in Spacers

Suitability of Spacers

Innovative Delivery Systems

Cutting Edge Developments in MDIs

Merits of pMDIs

Limitations

Issues MDIs

MDIs & Future

Supply of MDIs in Developing Nations

C. Dry Powder Inhalers (DPIs)

Inspiratory Flow Rate in DPIs

DPIs to Create Significant Impact

DPIs: Not Entirely a New Concept

Working Principle of DPIs

Deaggregation in Dry Powder Inhalers (DPIs)

Types of DPIs

Passive DPI

Active DPI

Single-dose DPIs

Multi-dose DPIs

Other Types

Development Activities in DPI

Cost Considerations

Benefits of DPI

Limitations

Issues

In a nutshell

Suitability of DPIs

Trends

Growth Areas

Comparison between MDI and DPI

Other Types of Inhalers

Single-Breath Liquid Based Systems

Multi Drug Atomizers

Liquid Sieving

Unit Dose Single Breath Atomizer

Side Effects of Inhalers

Side Effects in Children

5. An Overview of Pulmonary Conditions and Therapies

Drug Delivery to the Lung: An Insight

The Respiratory System

Methods of Drug Delivery through Pulmonary Route

Aerosols Systems

Intratracheal instillation

Insufflation

Pulmonary Delivery Approaches

Controlled Release

Asthma and COPD

Asthma: Primary Respiratory Syndrome

Trigger Factors

Magnitude of Disease

Chronic Obstructive Pulmonary Disease

Magnitude of Disease

Treatment of Asthma and COPD

Drug Medications for Treating Asthma and COPD

Bronchodilators (Acute Reliever Drugs)

Categories of Bronchodilators

Beta-agonists

Short acting beta-agonists

Long acting beta-agonists

Anti-cholinergics

Methylxanthines

Anti-Inflammatory Medication (Controllers or Preventers)

Inhaled glucocorticosteroids (or inhaled steroids)

Cromoglycate-like drugs

Other Delivery Routes for Asthma and COPD Treatment

Oral Route

New Oral Therapies

Injectable Option

Significance of Relievers and Preventers

Steroid MDIs and DPIs

Benefits of Pulmonary Drug Delivery Systems

Protein Absorption

Convenience

Bioavailability

Applications of Pulmonary Technology

Titration by Therapy

Titration by Patient

Dose Reproducibility

High Bioavailability

Types of Inhaler Devices

Aerosol Inhalers

Breath-Actuated Inhalers

Factors Influencing Clinical Effectiveness of Inhalation Device

Device Factors

Patient Factors

Drug Factors

6. Regulatory Environment

The Montreal Protocol

FDA Bans the Use of CFC’s in Metered Dose Inhalers

A Brief Overview of CFC-MDI Transition

Freon Compounds

HFC Emissions

Table 3: Ozone Depletion and Global Warming Impact of Various Propellants

Reformulation of MDIs

Suitable Non-CFCs

Country-wise Variations in CFC Transition

Preference for HFCs

Issues in HFC Use

HFC MDI Gaining Momentum

HFC MDIs Commercialization

Potential of HFC 227ea

7. Product Developments

Generex Biotechnology Corporation Receives Patent from Mexican Institute of Industrial Property

Spiriva® Ensures Relief to COPD Sufferers

Alkermes and Eli Lilly Initiates Phase 3 Clinical Study on AIR®

Sepracor Receives FDA Approval for Arformoterol Tartrate Inhalation Solution

Vectura Group Completes Phase-II Proof-of-Concept Study on VR040

Ventaira Conducts Pharmacokinetic Study on Fluticasone Propionate

Exubera® Inhalation Powder Receives FDA and European Commission Approval

LAB International Completes Phase I Trial on LAB CGRP

Xopenex HFA Receives FDA Approval

8. Product Innovations/Introductions

Consort Medical Releases Meter Dose Inhalers

Trinity Chiesi Pharmaceuticals Introduces Fostair

AstraZeneca Launches Symbicort®

Dey, L.P Unveils Perforomist™

Next Safety Rolls Out Hi-Performance Drug Delivery Technology

Bang & Olufsen Medicom Unveils Aspira™

Exaeris Launches MD Turbo™

Chiesi Farmaceutici Launches Clenil® Modulite® pMDI

GlaxoSmithKline Develops a New Advair Drug Formulation

9. Recent Industry Activity

Sepracor Signs Agreement with Nycomed

Kamada Enter into Strategic Pacts with Pari Pharma

GlaxoSmithKline Ties-Up with Amira Pharmaceuticals

BattellePharma Takes Over Ventaira Pharmaceuticals

Eurand Takes Over SourceCF

Aradigm Signs Agreement with Lung Rx for Developing AERx Essence(R) Technology

Vectura Inks Agreement with a European Company

ZYFLO CR™ Obtains FDA Clearance

SkyePharma Revises Agreement with Abott

Alnylam Presents Scientific Progress of ALN-RSV01

Bayer HealthCare and Nektar Therapeutics to Develop NKTR- 061

Graceway Snaps Up 3M Pharmaceuticals

Ventaira Pharmaceuticals Signs Agreement with Nypro

Novartis Forms Strategic Alliance with Schering-Plough

Aradigm Divests Intraject Subcutaneous Delivery Technology to Zogenix

Exaeris Inks Agreement with Teamm Pharmaceuticals

XstalBio Signs License Agreement with Boehringer Ingelheim

Alkermes Signs Agreement with Eli Lilly

Vectura Signs Agreement with Boehringer Ingelheim to Develop New Dry Powder Inhaler

Vectura Signs Collaboration Agreement for Combination Asthma Therapy

Lab Pharma and Teikoku Seiyaku Sign Licensing Agreement

Airpharma Enters into an Agreement with Bespak for Developing Inhalation Device

Eiffel Technologies Signs Agreement with MAP Pharmaceuticals

Inyx Acquires Celltech Manufacturing Services Limited

Nektar Therapeutics Acquires Aerogen, Inc

Chiesi Farmaceutici S.p.A. Enters into a Pact with NovartisPharma AG for Formoterol Modulite® HFA

Respirics Receives 510(k) Clearance for MD Turbo(TM) Device

Sanofi-Synthelabo Acquires Aventis

SkyePharma Plc Enters into a Strategic Alliance with Vectura

Bespak Plc Enters into an Agreement with Innovata Biomed

Chiesi Enters into an Agreement with Trudell Medical International

SkyePharma Plc and AstraZeneca Announce Completion of Phase III Trials of HFA-MDI Corticosteroid

Medical Industries Pens Agreement with ALR Technologies

Inyx Inc Forays into Dry Powder Inhalers Segment

BattellePharma Renamed Ventaira

Valois Purchases Rights to New Dry Powder Inhaler

10. Focus on Select Players

3M Drug Delivery Systems Division (USA)

Akela Pharma Inc. (Canada)

Alkermes Inc., (USA)

Aradigm Corporation (USA)

AstraZeneca Plc (UK)

Baxter Healthcare Corporation (USA)

Chiesi Farmaceutici SpA (Italy)

Consort Medical Plc (UK)

Dey L.P. (USA)

GlaxoSmithKline Plc (UK)

Graceway Pharmaceuticals, LLC (USA)

Nektar Therapeutics (USA)

Oriel Therapeutics Inc. (USA)

Sepracor Inc. (USA)

SkyePharma Plc (UK)

Vectura Group Plc (UK)

11. Global Market Perspective

Table 4: World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 5: World Long-term Projections for Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 6: World 10-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2008, and 2012 (includes corresponding Graph/Chart)

Table 7: World Recent Past, Current and Future Analysis for Metered Dose Inhalers (MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 8: World Long-term Projections for Metered Dose Inhalers (MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 9: World 10-Year Perspective for Metered Dose Inhalers (MDIs) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2008, and 2012 (includes corresponding Graph/Chart)

Table 10: World Recent Past, Current and Future Analysis for Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 11: World Long-term Projections for Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 12: World 10-Year Perspective for Dry Powder Inhalers (DPIs) by Geographic Region - PercentageBreakdown of Dollar Sales for US, Canada, Japan, Europe,Asia Pacific (excluding Japan), Latin America andRest of the World Markets for Years 2003, 2008,and2012 (includes corresponding Graph/Chart)

Table 13: World Recent Past, Current and Future Analysisfor Nebulizers by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 14: World Long-term Projections for Nebulizers by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 15: World 10-Year Perspective for Nebulizers by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2008, and 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A. Market Analysis

Outlook

Forecast for the Near Future

Nebulizers: Engraving High Market Interests

Table 16: US Market for Pulmonary Drug Delivery Technologies (2000, 2005 & 2010): Percentage Share Breakdown by Application Area - Asthma/COPD, Diabetes, Cancer, Cystic Fibrosis, and Migraine (includes corresponding Graph/Chart)

New Age Pulmonary Drug Delivery Technologies

Inhaled Prescription Drugs in the US: Ranking of Flovent (fluticasone), Serevent (salmeterol), Pulmicort Turbohaler (budesonide), Atrovent (ipratropium bromide), Ventolin (albuterol), Combivent (ipratropium bromide + albuterol sulfate), and Advair/Seretide (fluticasone + salmeterol)

Role of FDA

Metered Dose Inhalers

Non-CFC Metered Dose Inhalers

Table 17: U.S Market for Non-CFC Metered Dose Inhalers (2000, 2005 & 2010): Percentage Share Breakdown by Application Areas- Asthma/ COPD and Cancer

Table 18: Primary Manufacturers of Non-CFC Metered Dose Inhalers in the U.S (2004): Percentage Share Breakdown by 3M Drug Delivery Systems and GlaxoSmithKline

Dry Powder Inhalers

Table 19: US Market for Dry Powder Inhalers (2004): Percentage Share Breakdown of Value Sales by Major Players-GlaxoSmithKline, AstraZeneca and Novartis/ Schering- Plough (includes corresponding Graph/Chart)

Popular DPIs in the U.S

Trends in DPI Devices

Table 20: US Market for Dry Powder Inhalers (2000, 2005, & 2010): Percentage Share Breakdown by Application Areas- Asthma/COPD, Diabetes, Cystic Fibrosis, Cancer, and Migraine (includes corresponding Graph/Chart)

Drug Delivery Market in the U.S

Competitive Landscape

Product Launches/Developments

Strategic Corporate Developments

Select Players

B. Market Analytics

Table 21: US Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 22: US Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 23: US 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

2. Canada

A. Market Analysis

Outlook

Akela Pharma Inc. - A Major Player

B. Market Analytics

Table 24: Canadian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 25: Canadian Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 26: Canadian 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

3. Japan

A. Market Analysis

Outlook

Market Overview

Table 27: Japanese Market for Pulmonary Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Leading Brands-Atrovent, Beclovent, Ventolin, Serevent, Pulmicort, Flonase, and Others (includes corresponding Graph/Chart)

Market Highlights

Strategic Corporate Developments

Omron Healthcare Co. Ltd - A Major Player

B. Market Analytics

Table 28: Japanese Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 29: Japanese Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 30: Japanese 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

4. Europe

A. Market Analysis

Outlook

Transition to Non-CFC MDIs

Potential Hurdles in DPI Penetration in Europe

Market Awareness

Price Issues

Healthcare Effects

Patient Retraining

Strategic Corporate Development

B. Market Analytics

Table 31: European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 32: European Long-term Projections for Pulmonary Drug Delivery Technologies by Geographic Region - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart)

Table 33: European 10-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2003, 2008, and 2012 (includes corresponding Graph/Chart)

Table 34: European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 35: European Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 36: European 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

4a. France

A. Market Analysis

Outlook

Market Overview

Strategic Corporate Developments

B. Market Analytics

Table 37: French Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 38: French Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 39: French 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

4b. Germany

Market Analysis

Table 40: German Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 41: German Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 42: German 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

4c. The United Kingdom

A. Market Analysis

Outlook

Market Overview

Table 43: UK Market for Inhaled Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Major Brands- Serevent, Ventolin, Pulmicort, Flovent, Beclovent, Atrovent, Flonase, Vancenase Pocket, Vancenase, and Other (includes corresponding Graph/Chart)

Areas of Growth

Progress in Drug Delivery

Asthma Incidence among Children

Product Launches/Developments

Strategic Corporate Developments

Select Players

B. Market Analytics

Table 44: UK Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 45: UK Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 46: UK 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

4d. Italy

A. Market Analysis

Outlook

Competitive Landscape

Table 47: Italian Market for Pulmonary Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Major Brands- Pulmicort, Ventolin, Beclovent, Flovent, Serevent, Atrovent, Flonase, Vancenase Pocket, Vancenase, and Other (includescorresponding Graph/Chart)

Strategic Corporate Developments

Chiesi Farmaceutici SpA - A Major Italian Player

B. Market Analytics

Table 48: Italian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million forYears 2000 through 2010 (includes corresponding Graph/Chart)

Table 49: Italian Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 50: Italian 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

4e. Spain

A. Market Analysis

Outlook

Competitive Landscape

Table 51: Spanish Market for Pulmonary Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Leading Brands- Pulmicort, Beclovent, Serevent, Ventolin, Atrovent, Flonase, Flovent, Vancenase Pocket, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 52: Spanish Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 53: Spanish Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart)

Table 54: Spanish 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

4f. Russia

Market Analysis

Table 55: Russian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 56: Russian Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart)

Table 57: Russian 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

4g. Rest of Europe

A. Market Analysis

Outlook

Ireland

Growth of Systemic Drug Delivery Device Market in Chaos

Sweden

Prominent Position in DPIs

The Netherlands

Product Launch

Strategic Corporate Development

B. Market Analytics

Table 58: Rest of Europe Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 59: Rest of Europe Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 60: Rest of Europe 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

5. Asia-Pacific

A. Market Analysis

Outlook

China

Market Scenario

India

Market Scenario

Dry Powder Inhalers for Children

Device Prices

Australia

Asthma: The Most Common Chronic Suffering Among Australians

Australia Finding Preventives for Asthma Cure

Use of CFCs in Australia

B. Market Analytics

Table 61: Asia Pacific Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 62: Asia Pacific Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart)

Table 63: Asia Pacific 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart)

6. Latin America

A. Market Analysis

Outlook

Brazil

B. Market Analytics

Table 64: Latin America Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 65: Latin America Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 66: Latin America 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Salesfor Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,2008 and 2012 (includes correspondingGraph/Chart)

7. Rest of World

Market Analysis

Table 67: Rest of the World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered DoseInhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 68: Rest of the World Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 69: Rest of the World 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008 and 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 55 (including Division/Subsidiaries - 64)

Region/Country Players

The United States 38

Canada 2

Japan 3

Europe 20

France 1

Germany 1

The United Kingdom 10

Italy 2

Rest of Europe 6

Middle East 1

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.